INCY
Incyte Corporation
NASDAQ: INCY · HEALTHCARE · BIOTECHNOLOGY
$127.10
-2.18% today
Updated 2026-07-29
Market cap
$23.42B
P/E ratio
16.56
P/S ratio
4.37x
EPS (TTM)
$7.08
Dividend yield
—
52W range
$67 – $120
Volume
1.9M
Incyte Corporation (INCY) Insider transactions
Net insider activity
Net buying (161,444 shares)
Buy transactions
50
Sell transactions
50
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-15 | TRAY, THOMAS | Principal Accounting Officer | Sale | 1,098 | $115.09 | $126368.82 |
| 2026-07-15 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Sale | 28,237 | $113.05 | $3.19M |
| 2026-07-15 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Sale | 3,088 | $115.09 | $355397.92 |
| 2026-07-15 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 1,512 | $115.09 | $174016.08 |
| 2026-07-15 | ISSA, MOHAMED KHAIRIE | EVP, Head of U.S. Commercial | Sale | 1,099 | $115.09 | $126483.91 |
| 2026-07-15 | CAGNONI, PABLO J | President, Global Head of R&D | Sale | 4,950 | $115.09 | $569695.50 |
| 2026-07-14 | TRAY, THOMAS | Principal Accounting Officer | Sale | 692 | $114.88 | $79496.96 |
| 2026-07-14 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Sale | 21,830 | $114.88 | $2.51M |
| 2026-07-14 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 437 | $114.88 | $50202.56 |
| 2026-07-14 | CAGNONI, PABLO J | President, Global Head of R&D | Sale | 17,969 | $114.88 | $2.06M |
| 2026-07-02 | TRAY, THOMAS | Principal Accounting Officer | Sale | 477 | $116.86 | $55742.22 |
| 2026-07-02 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Sale | 2,177 | $116.86 | $254404.22 |
| 2026-07-02 | MEURY, WILLIAM | Director, Chief Executive Officer, President | Sale | 4,779 | $116.86 | $558473.94 |
| 2026-07-02 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 350 | $116.86 | $40901.00 |
| 2026-06-30 | HARRIGAN, EDMUND | Director | Buy | 255 | $113.36 | $28906.80 |
| 2026-06-30 | CLANCY, PAUL J | Director | Buy | 252 | $113.36 | $28566.72 |
| 2026-06-30 | BAKER, BROS. ADVISORS LP | Director, 10% Owner | Buy | 400 | — | — |
| 2026-06-08 | HIGH, KATHERINE A | Director | Buy | 6,111 | — | — |
| 2026-06-08 | HIGH, KATHERINE A | Director | Buy | 1,642 | — | — |
| 2026-06-08 | HARRIGAN, EDMUND | Director | Buy | 6,111 | — | — |
| 2026-06-08 | HARRIGAN, EDMUND | Director | Buy | 1,642 | — | — |
| 2026-06-08 | FOUSE, JACQUALYN A | Director | Buy | 6,111 | — | — |
| 2026-06-08 | FOUSE, JACQUALYN A | Director | Buy | 1,642 | — | — |
| 2026-06-08 | CLANCY, PAUL J | Director | Buy | 6,111 | — | — |
| 2026-06-08 | CLANCY, PAUL J | Director | Buy | 1,642 | — | — |
| 2026-06-08 | BRAWLEY, OTIS W | Director | Buy | 6,111 | — | — |
| 2026-06-08 | BRAWLEY, OTIS W | Director | Buy | 1,642 | — | — |
| 2026-06-08 | BIENAIME, JEAN JACQUES | Director | Buy | 6,111 | — | — |
| 2026-06-08 | BIENAIME, JEAN JACQUES | Director | Buy | 1,642 | — | — |
| 2026-06-08 | BAKER, BROS. ADVISORS LP | Director, 10% Owner | Buy | 6,111 | — | — |
| 2026-06-08 | BAKER, BROS. ADVISORS LP | Director, 10% Owner | Buy | 1,642 | — | — |
| 2026-06-04 | TRAY, THOMAS | Principal Accounting Officer | Sale | 2,639 | — | — |
| 2026-06-04 | TRAY, THOMAS | Principal Accounting Officer | Buy | 2,639 | $83.83 | $221227.37 |
| 2026-06-01 | CAGNONI, PABLO J | President, Global Head of R&D | Sale | 25,469 | $95.59 | $2.43M |
| 2026-05-26 | TRAY, THOMAS | Principal Accounting Officer | Sale | 2,051 | $97.35 | $199664.85 |
| 2026-05-26 | BIENAIME, JEAN JACQUES | Director | Sale | 15,000 | — | — |
| 2026-05-26 | BIENAIME, JEAN JACQUES | Director | Buy | 15,000 | $84.53 | $1.27M |
| 2026-05-26 | BIENAIME, JEAN JACQUES | Director | Sale | 13,059 | $97.10 | $1.27M |
| 2026-05-19 | CLANCY, PAUL J | Director | Sale | 15,000 | — | — |
| 2026-05-19 | CLANCY, PAUL J | Director | Sale | 15,000 | $94.93 | $1.42M |
| 2026-05-08 | BAKER, BROS. ADVISORS LP | Director, 10% Owner | Sale | 15,000 | — | — |
| 2026-05-08 | BAKER, BROS. ADVISORS LP | Director, 10% Owner | Buy | 15,000 | $84.53 | $1.27M |
| 2026-05-06 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Buy | 44,124 | — | — |
| 2026-05-06 | CAGNONI, PABLO J | President, Global Head of R&D | Buy | 31,517 | — | — |
| 2026-05-04 | UPADHYAY, SUKETU | EVP & Chief Financial Officer | Buy | 13,171 | — | — |
| 2026-05-04 | UPADHYAY, SUKETU | EVP & Chief Financial Officer | Buy | 38,429 | — | — |
| 2026-05-04 | UPADHYAY, SUKETU | EVP & Chief Financial Officer | Buy | 26,343 | — | — |
| 2026-04-17 | CAGNONI, PABLO J | President, Global Head of R&D | Sale | 12,590 | — | — |
| 2026-04-17 | CAGNONI, PABLO J | President, Global Head of R&D | Sale | 6,077 | — | — |
| 2026-04-17 | CAGNONI, PABLO J | President, Global Head of R&D | Sale | 18,667 | $96.50 | $1.80M |
| 2026-04-17 | CAGNONI, PABLO J | President, Global Head of R&D | Buy | 12,590 | $71.93 | $905598.70 |
| 2026-04-17 | CAGNONI, PABLO J | President, Global Head of R&D | Buy | 6,077 | $64.25 | $390447.25 |
| 2026-04-15 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Buy | 39,049 | — | — |
| 2026-04-15 | MEURY, WILLIAM | Director, Chief Executive Officer, President | Buy | 125,000 | — | — |
| 2026-04-15 | CAGNONI, PABLO J | President, Global Head of R&D | Buy | 27,892 | — | — |
| 2026-03-31 | HARRIGAN, EDMUND | Director | Buy | 269 | $94.12 | $25318.28 |
| 2026-03-31 | CLANCY, PAUL J | Director | Buy | 265 | $94.12 | $24941.80 |
| 2026-03-31 | BAKER, BROS. ADVISORS LP | Director, 10% Owner | Buy | 421 | — | — |
| 2026-03-25 | TROTTA, MATTEO | EVP, GM, Dermatology US | Sale | 537 | $92.23 | $49527.51 |
| 2026-03-17 | CAGNONI, PABLO J | President, R&D | Sale | 11,501 | — | — |
| 2026-03-17 | CAGNONI, PABLO J | President, R&D | Sale | 7,166 | — | — |
| 2026-03-17 | CAGNONI, PABLO J | President, R&D | Sale | 18,667 | $94.24 | $1.76M |
| 2026-03-17 | CAGNONI, PABLO J | President, R&D | Buy | 11,501 | $64.25 | $738939.25 |
| 2026-03-17 | CAGNONI, PABLO J | President, R&D | Buy | 7,166 | $61.18 | $438415.88 |
| 2026-02-19 | CAGNONI, PABLO J | President, R&D | Sale | 13,093 | — | — |
| 2026-02-19 | CAGNONI, PABLO J | President, R&D | Sale | 5,575 | — | — |
| 2026-02-19 | CAGNONI, PABLO J | President, R&D | Sale | 18,668 | $100.91 | $1.88M |
| 2026-02-19 | CAGNONI, PABLO J | President, R&D | Buy | 13,093 | $61.76 | $808623.68 |
| 2026-02-19 | CAGNONI, PABLO J | President, R&D | Buy | 5,575 | $61.18 | $341078.50 |
| 2026-02-02 | MORRISSEY, MICHAEL JAMES | EVP, Head of Tech. Operations | Sale | 185 | $102.67 | $18993.95 |
| 2026-02-02 | HEESON, LEE | EVP, Head of Incyte Intl | Sale | 111 | $102.67 | $11396.37 |
| 2026-01-20 | MORRISSEY, MICHAEL JAMES | EVP, Head of Tech. Operations | Sale | 429 | $102.62 | $44023.98 |
| 2026-01-16 | TROTTA, MATTEO | EVP, GM, Dermatology US | Buy | 8,542 | — | — |
| 2026-01-16 | TRAY, THOMAS | Principal Accounting Officer | Buy | 2,425 | — | — |
| 2026-01-16 | STEIN, STEVEN H | EVP & Chief Medical Officer | Buy | 19,932 | — | — |
| 2026-01-16 | MORRISSEY, MICHAEL JAMES | EVP, Head of Tech. Operations | Buy | 7,426 | — | — |
| 2026-01-16 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 4,218 | — | — |
| 2026-01-16 | ISSA, MOHAMED KHAIRIE | EVP, Head of US Oncology | Buy | 14,237 | — | — |
| 2026-01-16 | HEESON, LEE | EVP, Head of Incyte Intl | Buy | 8,911 | — | — |
| 2026-01-16 | CAGNONI, PABLO J | President, R&D | Buy | 28,475 | — | — |
| 2026-01-07 | ISSA, MOHAMED KHAIRIE | EVP, Head of US Oncology | Sale | 10,856 | $109.07 | $1.18M |
| 2026-01-06 | ISSA, MOHAMED KHAIRIE | EVP, Head of US Oncology | Sale | 8,264 | $106.66 | $881438.24 |
| 2026-01-05 | STEIN, STEVEN H | EVP & Chief Medical Officer | Sale | 15,634 | $101.70 | $1.59M |
| 2025-12-31 | STEIN, STEVEN H | EVP & Chief Medical Officer | Sale | 13,292 | $98.77 | $1.31M |
| 2025-12-31 | MORRISSEY, MICHAEL JAMES | EVP, Head of Tech. Operations | Sale | 254 | $98.77 | $25087.58 |
| 2025-12-31 | HARRIGAN, EDMUND | Director | Buy | 245 | $98.77 | $24198.65 |
| 2025-12-31 | CLANCY, PAUL J | Director | Buy | 241 | $98.77 | $23803.57 |
| 2025-12-31 | BAKER, BROS. ADVISORS LP | Director, 10% Owner | Buy | 328 | — | — |
| 2025-12-19 | TRAY, THOMAS | Principal Accounting Officer | Sale | 1,730 | — | — |
| 2025-12-19 | TRAY, THOMAS | Principal Accounting Officer | Sale | 1,044 | — | — |
| 2025-12-19 | TRAY, THOMAS | Principal Accounting Officer | Sale | 2,774 | $100.00 | $277400.00 |
| 2025-12-19 | TRAY, THOMAS | Principal Accounting Officer | Buy | 1,730 | $95.76 | $165664.80 |
| 2025-12-19 | TRAY, THOMAS | Principal Accounting Officer | Buy | 1,044 | $95.76 | $99973.44 |
| 2025-12-18 | TRAY, THOMAS | Principal Accounting Officer | Sale | 600 | $98.25 | $58950.00 |
| 2025-12-17 | MORRISSEY, MICHAEL JAMES | EVP, Head of Tech. Operations | Sale | 4,323 | $97.26 | $420454.98 |
| 2025-12-16 | MORRISSEY, MICHAEL JAMES | EVP, Head of Tech. Operations | Sale | 53,175 | $97.29 | $5.17M |
| 2025-12-16 | MORRISSEY, MICHAEL JAMES | EVP, Head of Tech. Operations | Sale | 833 | $97.42 | $81150.86 |
| 2025-12-11 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 255 | $94.94 | $24209.70 |
| 2025-12-10 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 5,553 | $95.58 | $530755.74 |
| 2025-12-08 | HOPPENOT, HERVE | Director | Sale | 2,843 | $96.70 | $274918.10 |
Frequently asked questions
Are INCY insiders buying or selling?
Over the transactions on record, INCY insiders have been net sellers, with about $32.88M in stock sold across 50 sales, against 17 open-market purchases.
Does insider selling at INCY mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which INCY insiders are selling the most?
Recent selling is concentrated in a few names. CAGNONI, PABLO J accounts for the largest share on record, with about $10.51M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.